Abstract:The majority of therapies that target individual proteins rely on specific activity-modulating interactions with the target protein—for example, enzyme inhibition or ligand blocking. However, several major classes of therapeutically relevant proteins have unknown or inaccessible activity profiles and so cannot be targeted by such strategies. Protein-degradation platforms such as proteolysis-targeting chimaeras (PROTACs)<a href="/articles/s41586-020-2545-9#ref-CR1">1</a>,<a href="/articles/s41586-020-2545-9#ref-CR2">2</a> and others (for example, dTAGs<a href="/articles/s41586-020-2545-9#ref-CR3">3</a>, Trim-Away<a href="/articles/s41586-020-2545-9#ref-CR4">4</a>, chaperone-mediated autophagy targeting<a href="/articles/s41586-020-2545-9#ref-CR5">5</a> and SNIPERs<a href="/articles/s41586-020-2545-9#ref-CR6">6</a>) have been developed for proteins that are typically difficult to target; however, these methods involve the manipulation of intracellular protein degradation machinery and are therefore fundamentally limited to proteins that contain cytosolic domains to which ligands can bind and recruit the requisite cellular components. Extracellular and membrane-associated proteins—the products of 40% of all protein-encoding genes<a href="/articles/s41586-020-2545-9#ref-CR7">7</a>—are key agents in cancer, ageing-related diseases and autoimmune disorders<a href="/articles/s41586-020-2545-9#ref-CR8">8</a>, and so a general strategy to selectively degrade these proteins has the potential to improve human health. Here we establish the targeted degradation of extracellular and membrane-associated proteins using conjugates that bind both a cell-surface lysosome-shuttling receptor and the extracellular domain of a target protein. These initial lysosome-targeting chimaeras, which we term LYTACs, consist of a small molecule or antibody fused to chemically synthesized glycopeptide ligands that are agonists of the cation-independent mannose-6-phosphate receptor (CI-M6PR). We use LYTACs to develop a CRISPR interference screen that reveals the biochemical pathway for CI-M6PR-mediated cargo internalization in cell lines, and uncover the exocyst complex as a previously unidentified—but essential—component of this pathway. We demonstrate the scope of this platform through the degradation of therapeutically relevant proteins, including apolipoprotein E4, epidermal growth factor receptor, CD71 and programmed death-ligand 1. Our results establish a modular strategy for directing secreted and membrane proteins for lysosomal degradation, with broad implications for biochemical research and for therapeutics.

Repurposing an endogenous degradation domain for antibody-mediated disposal of cell-surface proteins

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

Targeted Degradation of Cell‐Surface Proteins via Chaperone‐Mediated Autophagy by Using Peptide‐Conjugated Antibodies

Lysosome-targeting chimaeras for degradation of extracellular proteins

Development of Antibody-Based PROTACs for the Degradation of the Cell-Surface Immune Checkpoint Protein PD-L1

Harnessing the Lysosomal Sorting Signals of the Cation-Independent Mannose-6-Phosphate Receptor for Targeted Degradation of Membrane Proteins

Covalently Engineered Nanobody Chimeras for Targeted Membrane Protein Degradation

Peptide-Mediated Small Molecule Lysosome-Targeting Chimeras for Targeted Degradation of Membrane and Intracellular Proteins

Targeted protein degradation using chimeric human E2 ubiquitin-conjugating enzymes

Targeted protein degradation through site-specific antibody conjugation with mannose 6-phosphate glycan

A co-assembly platform engaging macrophage scavenger receptor A for lysosome-targeting protein degradation

Bispecific Aptamer Chimeras Enable Targeted Protein Degradation On Cell Membranes

Polymeric Lysosomal-Targeting Chimeras: Extracellular Targeted Protein Degradation Without Co-opting Lysosome-Targeting Receptors

Elucidating the cellular determinants of targeted membrane protein degradation by lysosome-targeting chimeras

Targeted clearance of senescent cells using an antibody-drug conjugate against a specific membrane marker

Therapeutic antibody engineering for efficient targeted degradation of membrane proteins in lysosomes

An all-in-one targeted protein degradation platform guided by degradation condensates-bridging bi-specific nanobodies

Engineering Antibody Fusion Proteins for Targeted Intracellular Therapeutic Delivery

Bridging the gap in protein targeting

Transferrin receptor targeting chimeras for membrane protein degradation

Nanogel‐Facilitated Protein Intracellular Specific Degradation Through Trim‐Away